ISSN (Print): 2328-7322

ISSN (Online): 2328-7314


Editor-in-chief: Nabil Abdel-Hamid

You are here

Currrent Issue: Volume 3, Number 4, 2015


Tripterygium Wilfordii Extract (Triptolide) and Amygdalin Promotes Cell death in Cancer Cells: True or a Myth

1School of Medicine, European University Cyprus, Nicosia Cyprus

American Journal of Cancer Prevention. 2015, 3(4), 77-83
doi: 10.12691/ajcp-3-4-3
Copyright © 2015 Science and Education Publishing

Cite this paper:
Patrikios Ioannis, Stephanou Anastasis, Yiallouris Andreas. Tripterygium Wilfordii Extract (Triptolide) and Amygdalin Promotes Cell death in Cancer Cells: True or a Myth. American Journal of Cancer Prevention. 2015; 3(4):77-83. doi: 10.12691/ajcp-3-4-3.

Correspondence to: Patrikios  Ioannis, School of Medicine, European University Cyprus, Nicosia Cyprus. Email:;


Different natural products are known for their use in conventional medicine and especially for their beneficial effect on chronic diseases including autoimmune and cancer. A purified natural extract sample from the Chinese herb Tripterygium wilfordii Hook F (known as Lei Gong Teng or Thunder of God Vine) containing diterpenoids and triepoxides, was associated with significant anti-tumor effects and with encouraging results. Additionally, another natural extract from apricot kernels, Amygdalin (also known as laetrile or vitamin B17) a cyanide- containing substance, has been reported as a potential anti-cancer molecule with numerous contradictions among different published data. For many years different scientist tried to investigate in vivo, in vitro and ex vivo the efficacy of all of these molecules but they all failed in giving clear robust positive conclusions and the opinions are contradictory. Most of the studies were focusing on the apoptotic effects that can lead to the programmed cell death (PCD), a noteworthy mechanism in cancer treatment. The present review summarizes published reports and gives a better understanding of the known abilities as well as the possible role of these specific natural extract molecules in the fight of cancer treatment, cure and prevention.



[1]  Corson, T.W.; Crews, C.M. Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell 2007, 130, 769-774.
[2]  Zhou, G.B.; Chen, S.J.; Wang, Z.Y.; Chen, Z. Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res. 2007, 17,274-276.
[3]  Helmstädter, A. Tripterygium wilfordii Hook. f. – how a traditional Taiwanese medicinal plant found its way to the West. Die Pharmazie - Die Pharmazie - An International Journal of Pharmaceutical Sciences. 2013, 68, 7, 643-646(4).
[4]  Goldbach-Mansky, R.; Wilson, M.; Fleischmann, R.; Olsen, N.; Silverfield, J.; Kempf, P.; Kivitz, A.; Sherrer, Y.; Pucino, F.; Csako, G.; et al. Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis A Randomized Trial. Ann. Intern. Med. 2009, 151, 229-251.
[5]  Tao, X.L.; Lipsky, P.E. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum. Dis. Clin. N. Amer. 2000, 26, 29 50.
Show More References
[6]  Ren, J.; Tao, Q.S.; Wang, X.B.; Wang, Z.M.; Li, J.S. Efficacy of T2 in active Crohn's disease: A prospective study report. Dig. Dis. Sci. 2007, 52, 1790-1797.
[7]  Ji, S.M.; Wang, Q.W.; Chen, J.S.; Sha, G.Z.; Liu, Z.H.; Li, L.S. Clinical trial of Tripterygium wilfordii Hook F. in human kidney transplantation in China. Transplant. Proc. 2006, 38, 1274-1279.
[8]  Chan, E.W.C.; Cheng, S.C.S.; Sin, F.W.Y.; Xie, Y. Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol. Lett. 2001, 122, 81-87.
[9]  Carter, B.Z.; Mak, D.H.; Schober, W.D.; Dietrich, M.F.; Pinilla, C.; Vassilev, L.T.; Reed, J.C.; Andreeff, M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008, 111, 3742-3750.
[10]  Zhou, G.S.; Hu, Z.; Fang, H.T.; Zhang, F.X.; Pan, X.F.; Chen, X.Q.; Hu, A.M.; Xu, L.; Zhou, G.B. Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk. Res. 2011, 35, 214-218.
[11]  Jiang, X.H.; Wong, B.C.Y.; Lin, M.C.M.; Zhu, G.H.; Kung, H.F.; Jiang, S.H.; Yang, D.; Lam, S.K. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappa B activation in gastric cancer cells. Oncogene 2001, 20, 8009-8018.
[12]  Chen, Y.W.; Lin, G.J.; Chia, W.T.; Lin, C.K.; Chuang, Y.P.; Sytwu, H.K. Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivo. Oral Oncol. 2009, 45, 562-568.
[13]  Wang, Z.P.; Jin, H.F.; Xu, R.D.; Mei, Q.B.; Fan, D.M. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp. Mol. Med. 2009, 41, 717-727.
[14]  Liu, Y.A.; Zeng, L.L.; Chen, Y.; Zhao, F.; Li, R.; Zhang, C.; Wen, L. Triptolide inhibits cell growth and induces G0-G1 arrest by regulating P21wap1/cip1 and P27 kip1 in human multiple myeloma RPMI-8226 cells. Chin. J. Cancer Res. 2010, 22, 141-147.
[15]  Kim, M.J.; Lee, T.H.; Kim, S.H.; Choi, Y.J.; Heo, J.; Kim, Y.H. Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. Int. J. Oncol. 2010, 37, 1177-1185.
[16]  Tengchaisri, T.; Chawengkirttikul, R.; Rachaphaew, N.; Reutrakul, V.; Sangsuwan, R.; Sirisinha, S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett. 1998, 133, 169-175.
[17]  Mujumdar, N.; Mackenzie, T.N.; Dudeja, V.; Chugh, R.; Antonoff, M.B.; Borja-Cacho, D.; Sangwan, V.; Dawra, R.; Vickers, S.M.; Saluja, A.K. Triptolide Induces Cell Death in Pancreatic Cancer Cells by Apoptotic and Autophagic Pathways. Gastroenterology 2010, 139, 598-608.
[18]  Antonoff, M.B.; Chugh, R.; Skube, S.J.; Dudeja, V.; Borja-Cacho, D.; Clawson, K.A.; Vickers, S.M.; Saluja, A.K. Role of Hsp-70 in triptolide-mediated cell death of neuroblastoma. J. Surg. Res. 2010, 163, 72-78.
[19]  Yang, S.M.; Chen, J.G.; Guo, Z.; Xu, X.M.; Wang, L.P.; Pei, X.F.; Yang, J.; Underhill, C.B.; Zhang, L.R. Triptolide inhibits the growth and metastasis of solid tumors. Mol. Cancer Ther. 2003, 2, 65-72. Molecules 2011, 16 5293.
[20]  Phillips, P.A.; Dudeja, V.; McCarroll, J.A.; Borja-Cacho, D.; Dawra, R.K.; Grizzle, W.E.; Vickers, S.M.; Saluja, A.K. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007, 67, 9407-9416.
[21]  Antonoff, M.B.; Chugh, R.; Borja-Cacho, D.; Dudeja, V.; Clawson, K.A.; Skube, S.J.; Sorenson, B.S.; Saltzman, D.A.; Vickers, S.M.; Saluja, A.K. Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery 2009, 146, 282-290.
[22]  Shamon, L. A., Pezzuto, J. M., Graves, J. M., Mehta, R. R., Wangcharoentrakul, S., Sangsuwan, R., Chaichana, S., Tuchinda, P., Cleason, P., and Reutrakul, V. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett., 1997, 112: 113-117.
[23]  Wei, Y. S., and Adachi, I. Inhibitory effect of triptolide on colony formation of breast and stomach cancer cell lines. Zhongguo Yaoli Xuebao, 1991, 12: 406-410.
[24]  Graziose, R.; Lila, M.A.; Raskin, I. Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr. Drug Discov. Technol. 2010, 7, 2-12.
[25]  Lipsky, P.E.; Tao, X.L. A potential new treatment for rheumatoid arthritis: Thunder god vine. Semin. Arthritis Rheum. 1997, 26, 713-723.
[26]  Ma, J.; Dey, M.; Yang, H.; Poulev, A.; Pouleva, R.; Dorn, R.; Lipsky, P.E.; Kennelly, E.J.; Raskin, I. Anti-inflammatory and immuno suppressive compounds from Tripterygium wilfordii. Phytochemistry 2007, 68, 1172-1178.
[27]  Qian, S.Z. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception 1987, 36, 335-345.
[28]  Matlin, S.A.; Belenguer, A.; Stacey, V.E.; Qian, S.Z.; Xu, Y.; Zhang, J.W.; Sanders, J.K.; Amor, S.R.; Pearce, C.M. Male antifertility compounds from Tripterygium wilfordii Hook f. Contraception 1993, 47, 387-400.
[29]  Chang H. K., Yang H. Y., Lee T. H., Shin M. C., Lee M. H., Shin M. S., Kim C. J., Kim O. J., Hong S. P., Cho S., Armeniacae semen extract suppresses lipopolysaccharide-induced expressions of cyclooxygenase [correction of cycloosygenase]-2 and inducible nitric oxide synthase in mouse BV2 microglial cells. Biol. Pharm. Bull., 2005, 28, 449-454.
[30]  Hwang DR, Kang YS, Kim SS, Kim DH, Shin MK, Song HJ. Studies on the Allergic asthma effect of Semen Armeniaceae Amarum. Kor j herbol. 2003; 18:201-208.
[31]  Pak JU, Moon SJ, Moon K, Won JH. Effects of Seman Armenicae and Radix Trichosanthis on the iNOS expression and superoxide formation in the RAW264.7 cells. J Kor Orient Oncol. 1999; 5:137-150.
[32]  Ellison NM, Byar DP, Newell GR. Special report on Laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective Laetrile analysis. N Engl J Med. 1978; 299:549-552.
[33]  Fukuda T, Ito H, Mukainaka T, Tokuda H, Nishino H, Yoshida T. Anti-tumor promoting effect of glycosides from Prunus persica seeds. Biol Pharm Bull. 2003; 26:271-273.
[34]  Shim B. S., Park J. K., Choi S. H., J. Kor. Orient. Oncol., 6, 2000, 19-28.
[35]  Koo J. Y., Hwang E. Y., Cho S., Lee J. H., Lee Y. M., Hong S. P., Quantitative determination of amygdalin epimers from armeniacae semen by liquid chromatography J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 814, 69-73.
[36]  Flora KP, Cradock JC, Ames MM. A simple method for the estimation of amygdalin in the urine. Res Commun Chem Pathol Pharmacol 1978; 20: 367-378.
[37]  Khandekar JD, Edelman H. Studies of amygdalin (laetrile) toxicity in rodents. JAMA 1979; 242: 169-171.
[38]  Moertel CG, Ames MM, Kovach JS, Moyer TP, Rubin JR, Tinker JH. A pharmacologic and toxicological study of amygdalin. JAMA 1981; 245: 591-594.
[39]  Fukuda T, Ito H, Mukainaka T, Tokuda H, Nishino H, Yoshida T. Anti-tumor promoting effect of glycosides from Prunus persica seeds. Biol Pharm Bull 2003; 26: 271-273.
[40]  Kwon HY, Hong SP, Hahn DH, Kim JH. Apoptosis induction of Persicae Semen extract in human promyelocytic leukemia (HL-60) cells. Arch Pharm Res. 2003; 26: 157-161.
[41]  Taija MK, Philip SL, Robert GS, et al. Antiproliferative and Proapoptotic Activities of Triptolide (PG490), a Natural Product Entering Clinical Trials, on Primary Cultures of Human Prostatic Epithelial Cells. Clin Cancer Reserch 2002:8:2666-2674.
[42]  Fei Z, Weiwei H, Tamgue O, Bin Z, Yangyang H, Daguia Z, John C, Chen W, Huanhuan C, Huanan L, Xiaoyong R, Ming Lei. Triptolide Induces Growth Inhibition and Apoptosis of Human Laryngocarcinoma Cells by Enhancing p53 Activities and Suppressing E6-Mediated p53 Degradation. Molecules 2013: V:8 Issue 11 e80784.
[43]  Zhipeng W, Haifeng J, Ruodan X, Qibing M, and Daiming F. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression EXPERIMENTAL and MOLECULAR MEDICINE, 2009. Vol. 41, No. 10, 717-727.
[44]  Hyun-Kyung C, Mal-Soon S, Hye-Young Y, Jin-Woo L, Young-Sick K, Myoung-Hwa L, Jullia K, Khae-Hawn K, and Chang-Ju K. Amygdalin Induces Apoptosis through Regulation of Bax and Bcl-2 Expressions in Human DU145 and LNCaP Prostate Cancer Cells. Biol. Pharm. Bull. 2006. 29 (8) 1597.
[45]  Milazzo, S., Lejeune, S. & Ernst, E. Laetrile for cancer: a systematic review of the clinical evidence. Support. Care Cancer 15, 583-595 (2007).
[46]  Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer N Engl J Med 1982. 306: 201-206.
[47]  Newell GR, Ellison NM Ethics and designs: laetrile trials as an example. Cancer Treat 1980. Rep 64: 363-365.
[48]  Yi D, Yi N. and Mavi A. Antioxidant and antimicrobial activities of bitter and sweet apricot (Prunus armeniaca L) kernels. Brazilian Journal of Medical and Biological Research 2009 42: 346 352 SSN 0100-879X.
[49]  Hae-Jeong P, Seo-Hyun Y, Long-Shan H, Long-Tai Z, Kyung-Hee J, Yoon-Kyung U, Je-Hyun L, Ji-Seon J, Woo-Sang J, Sung-Vin Y, Joo-Ho C, Seon-Pyo H. Amygdalin inhibits genes related to cell cycle in SNU C4 human colon cancer cells. World Journal of Gastroenterology 2005 ISSN 1007-9327.
[50]  Peng B, Miao MS, Wang YL, et al. Initial discussion of mice acute hepatic injury caused by tripterygium glycosides [in Chinese]. Zhongguo Zhong Yao Za Zhi. 2004;28:1067-70.
[51]  Takei A, Nagashima G, Suzuki R, et al. Meningoencephalocele associated with Tripterygium wilfordii treatment. Pediatr Neurosurg. 1997; 27:45-48.
[52]  Chan WY, Ng TB. Adverse effect of Tripterygium wilfordii extract on mouse embryonic development. Contraception. 1995;51:65-71.
[53]  Xu W, Ziqing L, Yinrun D, et al. Tripterygium hypoglaucum (level) Hutch induces aneuploidy of chromosome 8 in mouse bone marrow cells and sperm. Mutagenesis. 2004; 19:379-82.
[54]  Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am. 2000; 26:29-50, viii.
[55]  Lopez LM, Grimes DA, Schulz KF. Nonhormonal drugs for contraception in men: a systematic review. Obstet Gynecol Surv. 2005; 60(11):746-752.
[56]  Lue Y, Sinha Hikim AP, Wang C, et al. Triptolide: a potential male contraceptive. J Androl. 1998; 19(4):479-486.
[57]  Zhen Q, Ye X, Wei ZJ. Recent progress in research on Tripterygium: a male antifertility plant. Contraception. 1995; 51(2): 121-129.
[58]  Matlin SA, Belenguer A, Stacey VE, et al. Male antifertility compounds from Tripterygium wilfordii Hook f. Contraception.1993; 47(4):387-400.
[59]  Qian SZ. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception. 1987; 36(3):335-345.
[60]  Ji SM, Wang QW, Chen JS, Sha GZ, Liu ZH, Li LS. Clinical trial of Tripterygium wilfordii Hook F. in human kidney transplantation in China. Transplant Proc. 2006; 38(5):1274-1279.
[61]  Ji SM, Li LS, Wen JQ, et al. Therapeutic effect of Tripterygium wilfordii on proteinuria associated with sirolimus in renal transplant recipients. Transplant Proc. 2008; 40(10):3474-3478.
[62]  Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract. 2009;111(4):c223-c228.
[63]  Li XW, Weir MR. Radix Tripterygium wilfordii a Chinese herbal medicine with potent immunosuppressive properties. Transplantation. 1990;50(1):82-86.
[64]  Chang DM, Chang WY, Kuo SY, Chang ML. The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol. 1997;24(3):436-441.
[65]  Tao X, Davis LS, Lipsky PE. Effect of an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F on human immune responsiveness. Arthritis Rheum. 1991;34(10):1274-1281.
[66]  Ye WH. Mechanism of treating rheumatoid arthritis with polyglycosides of Tripterygium wilfordii Hook (T II). III. Study on inhibitory effect of T II on in vitro Ig secreted by peripheral blood mononuclear cells from normal controls and RA patients [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1990; 12(3): 217-222.
[67]  Sylvester J, Liacini A, Li WQ, Dehnade F, Zafarullah M. Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-kappaB activities. Mol Pharmacol. 2001;59(5):1196-1205.
[68]  Tao X, Cai JJ, Lipsky PE. The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook. F. J Pharmacol Exp Ther. 1995;272(3):1305-1312.
[69]  Tamaki T, Kawamura A, Komatsu Y, Kawamura H, Maruyama H, Morota T. Phenolic nortriterpene demethylzeylasteral: a new immunosuppressive component of Tripterygium wilfordii Hook f. Transplant Proc. 1996;28(3):1379-1380.
[70]  Yu DQ, Zhang DM, Wang HB, Liang XT. Structure modification of triptolide, a diterpenoid from Tripterygium wilfordii [in Chinese]. Yao Xue Xue Bao. 1992;27(11):830-836.
[71]  Little CV, Parsons T. Herbal therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2001;(1):CD002947.
[72]  Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blümle A, Chrubasik S. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 2: rheumatoid arthritis. Phytother Res. 2009;23(12):1647-1662.
[73]  Tao XL, Sun Y, Dong Y, et al. A prospective, controlled, double-blind, cross-over study of Tripterygium wilfordii hook F in treatment of rheumatoid arthritis. Chin Med J (Engl). 1989; 102(5): 327-332.
[74]  Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 2002;46(7):1735-1743.
[75]  Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med. 2009;151(4):229-240, W49-W51.
[76]  Conn EE: Cyanogenic glycosides, In Neuberger A, Jukes TH (Eds): International Review of Biochemistry, Biochemistry of Nutrition. Baltimore, Universty Park Press, 1979, pp 21-43.
[77]  Herbert V: Laetrile: The cult of cyanide-Promoting poison for profit. Am J Clin. Nutr. 1979. 32:1121-1158.
[78]  Griffin GE: World Without Cancer-The Story of Vitamin B1,7. Thousand Oaks, CA, American Media, 1974.
[79]  Lewis JP: Laetrile (Informed Opinion). West J Med. 1977. 127: 55-62,
[80]  Schmidt ES, Newton GW, Saunders SM, et al: Laetrile toxicity studies in dogs. JAMA 1978. 239:943-947.
[81]  Khandekar JD, Edelman H: Studies of amygdalin (laetrile) toxicity in rodents. JAMA 1979. 242:169-171.
[82]  Smith FP, Butler TP, Cohan S, et al: Laetrile toxicity: A report of two cases. Chem Treat Rep 1978. 62:169-171.
[83]  Humbert JR, Tress JH, Braico KT: Fatal cyanide poisoning: Accidental ingestion of amygdalin. JAMA 1977. 238:482.
[84]  Sadoff L, Fuchs K, Hollander J: Rapid deaths associated with laetrile ingestion. JAMA 1978. 239:1532.
[85]  Verdict of the coroner in the matter of the death of Jo Anne Etta Pye, February 1, 1979. Pathologist's Report Jan 26.
[86]  Investigator's Report December 3, 1978. Alameda County Coroner's Department, County of Alameda, Oakland, CA.
[87]  Anonymotus. Death blamed on cyanide-laetrile link. San Francisco Chronicle February 6, 1979.
[88]  Anonymous. Laetrile poisoning takes third life, threatens fourth. Med. World News 20: 32, 1979.
[89]  Ortega JA, Creek JE. Acute cyanide poisoning following administration of Laetrile J. Pediatr. 1978; 93: 1059.
Show Less References


Gemcitabine and Cisplatin Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report

1Department of Medical Oncology, Yuzuncu Yil University Medical Faculty, Van,Turkey

2Department of Radiology, Van Training and Research Hospital, Van, Turkey

3Department of Internal Medicine, Van Training and Research Hospital, Van, Turkey

4Department of Anesthesiolgy, Van Training and Research Hospital, Van, Turkey

5Department of Radiology, Yuzuncu Yil University Medical Faculty, Van,Turkey

American Journal of Cancer Prevention. 2015, 3(4), 74-76
doi: 10.12691/ajcp-3-4-2
Copyright © 2015 Science and Education Publishing

Cite this paper:
Erkan Dogan, Cemile Ayse Gormeli, Mehmet Fatih Ozbay, Edip Gonullu, Alper Can, Harun Arslan. Gemcitabine and Cisplatin Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report. American Journal of Cancer Prevention. 2015; 3(4):74-76. doi: 10.12691/ajcp-3-4-2.

Correspondence to: Erkan  Dogan, Department of Medical Oncology, Yuzuncu Yil University Medical Faculty, Van,Turkey. Email:


Background: Reversible Posterior Leukoencephalopathy Syndrome (RPLS) is a rare clinic-radiological condition. The clinical characteristics of this syndrome are headache, seizures, visual disturbances, confusion, and changes in mental status and focal neurological signs. The radiological characteristic of RPLS is bilateral symmetrical reversible vasogenic edema in the grey and white matter of the posterior part of the parietal-occipital lobes, consistent with hyperintensity in magnetic resonance imaging and computer tomography scans of the brain. Herein we report RPLS during the therapy with gemcitabine and cisplatin in a female patient with pancreatic cancer. Case Report: A 66-year-old female patient was admitted to the hospital because of abdominal pain. The results of computer tomography scans of the abdomen showed a 6-cm mass lesion in the tail of the pancreas and multiple metastatic lesions in the liver. A ‘tru-cut’ biopsy of the liver lesion proved to be consistent with adenocarcinoma. A combination chemotherapy regimen consisting of gemcitabine and cisplatin was planned. During this therapy, RPLS developed as a complication. Subsequent administration of chemotherapy was cancelled, and antihypertensive and anti-edema treatments were begun. Following this treatment the patient’s symptoms rapidly improved. There was a dramatic decline in vasogenic edema in control MRI scans which were performed a week later. Conclusion: Failure to diagnose the RPLS and correct the precipitating cause may result in catastrophic permanent brain injury or even death.



[1]  Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome, N Engl J Med, 334 (8), 494-500, 1996.
[2]  Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol, 27 (4), 1436-7, 2010.
[3]  Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.Oncologist, 12 (11), 1332-5, 2007.
[4]  Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc, 85(5), 427-32, 2010.
[5]  Port JD, Beauchamp NJ Jr. Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics, 18 (2), 353-67, 1998.
Show More References
[6]  Bartynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. Am J Neuroradiol. 29 (3), 447-55, 2008.
[7]  Sclafani F, Giuseppe G, Mezynksi J, Collins C, Crown J. Reversible posteriorleukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol, 30 (26), e257-9, 2012.
[8]  Femia G, Hardy TA, Spies JM, Horvath LG. Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review. Asia Pac J Clin Oncol, 8 (2), 115-22, 2012.
Show Less References


Solitary Plasmacytoma in the Oral cavity: A Case Report

1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

3Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

American Journal of Cancer Prevention. 2015, 3(4), 72-73
doi: 10.12691/ajcp-3-4-1
Copyright © 2015 Science and Education Publishing

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Jalil Hamidi. Solitary Plasmacytoma in the Oral cavity: A Case Report. American Journal of Cancer Prevention. 2015; 3(4):72-73. doi: 10.12691/ajcp-3-4-1.

Correspondence to: Masoud  Sadeghi, Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email:


Background: The plasma cell neoplasms may present in soft tissue as extramedullary plasmacytomas, in bone as a solitary plasmacytoma of bone, or as part of the multifocal disseminated disease multiple myeloma. The aim of study is to report solitary plasmacytoma in the oral cavity in a male patient. Case Report: A 65-year-old male was presented to our Clinic with hypertension, high fever and loss of balance. He had nine months ago one localized lytic lesion in his thoracic vertebrae T5. The clinical reports showed multiple myeloma for him. After that, He received melphalan and thalidomide for two months. The patients referred to Clinic again with a new oral lesion. In his treatment follow-up and biopsy from his new oral lesion, pathologist reported plasmacytoma. He was treated with radiotherapy(5.000 cGy), than received maintenance consisted of thalidomide 50 mg (VAD). He died after three months from treatment with VAD. Conclusion: The SPB is as part of the multifocal disseminated disease MM. Also, radiotherapy (5.000 cGy) and VAD are not optimal treatments for SPB.



[1]  Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol. 3(3):255-9.2002.
[2]  Dagan R, Morris CG, Kirwan J, Mendenhall WM. Solitary plasmacytoma. Am J Clin Oncol. 32(6):612-7.2009.
[3]  Mendenhall WM, Mendenhall CM, Mendenhall NP. Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol. 24(6):395-9.2003.
[4]  Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 96(6):2037-44.2000.
[5]  Regezi JA, Sciubba JJ, Jordan RCK. Oral Pathology: Clinical Pathologic Correlations. 4th Edn. Philadelphia, W.B. Saunders. 2003.
Show More References
[6]  Barros TP, Savilha FM, Amantea DV, Campolongo GD, Neto LB, Alves N, et al. Plasmacytoma in the oral cavity: A case report. Int J Odontostomat. 5(2):115-118. 2011.
[7]  Galieni P, Cavo M, Pulsoni A, Avvisati G, Bigazzi C, Neri S, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. Jan .85(1):47-51.2000.
[8]  Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park). Jan .14(1):101-8.2000.
[9]  Romero IL, Campos FA, Damasceno RW, Vital Filho J, Bison SH. Plasmacytoma of the orbit involving lacrimal gland with secondary transformation into multiple myeloma: case report. Arq Bras Oftalmol. 72(2):236-8.2009.
Show Less References